Coherus BioSciences, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus BioSciences, Inc. (CHRS) on September 11, 2023. The filing reports on a material definitive agreement regarding the company's "at-the-market" (ATM) equity offering program with TD Cowen.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the adjustment to the aggregate offering price under the ATM Sales Agreement.
- Previous ATM Cap (May 2023): $63.75 million (reduced from $150.0 million).
- New ATM Cap (September 2023): $92.5 million.
- Amount of Increase: $28.75 million.
Material Changes
On September 11, 2023, the Company executed Amendment No. 2 to its Sales Agreement with TD Cowen. This amendment increased the aggregate offering price available under the ATM program by $28.75 million, raising the total capacity from $63.75 million to $92.5 million. This follows a reduction in the program's capacity announced in May 2023.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose specific risks or contingencies beyond the standard qualification that the descriptions of the amendments are not complete and are subject to the full text of the agreements filed as exhibits to the Company's Form 10-Q reports.
Investor Verification Checklist
- Verify the full text of Amendment No. 2 to the Sales Agreement in the upcoming Form 10-Q for the quarter ending September 30, 2023.
- Review the Company's current cash position and burn rate to assess the necessity of the increased ATM capacity.
- Monitor future 8-K filings for actual share issuances under the expanded $92.5 million ATM program.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.